Is BrainsWay Ltd. (BRSYF) a Buy, Sell, or Hold?
OTC : BRSYF
BrainsWay Ltd. — News
$15.13 USD
$0 (0.0%)
- Volume
- 300
- Average Volume
- 12
- Market Capitalization
- $607.19M
- P/E Ratio
- 67.94
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $16.84
- Year Low
- $5.49
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.34
| Source | Headline |
|---|---|
|
BrainsWay Reports Favorable Coverage for Accelerated Deep TMS™ Rises to Over 57 Million Covered Lives
BURLINGTON, Mass. and JERUSALEM, June 22, 2026 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced further expansion in the number of medical policies across the U.S. providing favorable coverage for its SWIFT™ Accelerated Deep TMS™ protocol. The announcement comes after a series of favorable policy changes, the latest of which is a recently issued policy covering 2 million members in South Carolina allowing for coverage of SWIFT, in addition to various other increases in Deep TMS coverage for both major depressive disorder (MDD) and obsessive-compulsive disorder (OCD) patients. globenewswire.com - 2026-06-22 07:30:00 |
|
BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript
BrainsWay Ltd. (BWAY) Q1 2026 Earnings Call Transcript seekingalpha.com - 2026-05-13 11:20:48 |
